Stryker Hip Lawsuits Move Forward in New Jersey, As Court Overseeing LFIT V40 Femoral Head Claims Issues New Orders, Bernstein Liebhard LLP Reports
NEW YORK, July 3, 2017 /PRNewswire/ — Product liability claims involving Stryker’s recalled LFIT Anatomic CoCr V40 Femoral Heads are moving forward in the multicounty litigation currently underway in New Jersey’s Bergen County Superior Court. A Case Management Order dated June 26th stipulates, among other things, that all plaintiffs submit a completed Case Questionnaire by August 1, 2017. Those who file a lawsuit after June 2, 2017 must submit their questionnaire no later than 60 days from the filing of a responsive pleading. The Court also issued an Order extending the discovery deadline until December 31, 2018 for all cases in which it has already expired. (In re: Stryker LFIT Anatomic CoCr V40 Femoral Heads Litigation, case number 624)
«Our Firm is representing a number of clients who are seeking to pursue lawsuits involving Stryker’s LFIT V40 femoral heads. We will continue to monitor the proceeding in New Jersey, as well as the federal multidistrict litigation in New York, for any developments that could impact these cases,» says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering free, no-obligation legal reviews to individuals who may have been harmed by Stryker’s LFIT Anatomic Cobalt Chromium V40 femoral heads.
Stryker Hip Litigation
Stryker’s LFIT Anatomic CoCr V40 Femoral Heads are designed to be used with several of the company’s modular hip devices, including:
- Accolade TMZF
- Accolade 2 Stems
- Meridian Stems
- Citation Stems
Certain of these devices manufactured prior to 2011 were recalled by the company in August 2016, following an unusually high number of reports involving taper lock failure. Taper lock failure may result in loosening of the artificial joint and other debilitating complications, resulting in the need for revision surgery. The U.S. Food & Drug Administration (FDA) designated Stryker’s action a Class II recall, which indicates that the affected femoral heads could cause temporary or medically-reversible health consequences.
In May, the New Jersey Supreme Court transferred all state lawsuits involving LFIT V40 femoral heads before a single judge in Bergen County for the purposes of centralized case management. A month earlier, a centralized docket was established in the U.S. District Court, Southern District of New York, for all federally-filed involving the recalled components. (In RE: Stryker Orthopaedics LFIT V40 Femoral Head Product Liability Litigation, MDL NO. 2768)
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal’s «Plaintiffs’ Hot List,» recognizing the top plaintiffs firms in the country. This year’s nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stryker-hip-lawsuits-move-forward-in-new-jersey-as-court-overseeing-lfit-v40-femoral-head-claims-issues-new-orders-bernstein-liebhard-llp-reports-300483017.html
SOURCE Bernstein Liebhard LLP